Skip to main content
Current Oncology logoLink to Current Oncology
. 2008 Jan;15(1):53–62. doi: 10.3747/co.2008.201

Radiation recall dermatitis: case report and review of the literature

AE Hird *, J Wilson , S Symons , E Sinclair *, M Davis *, E Chow *,
PMCID: PMC2259426  PMID: 18317586

Abstract

“Radiation recall”—also called “radiation recall dermatitis”—has been defined as the “recalling” by skin of previous radiation exposure in response to the administration of certain response-inducing drugs. Although the phenomenon is relatively well known in the medical world, an exact cause has not been documented. Here, we report a rare occurrence of the radiation recall phenomenon in a breast cancer patient after palliative radiotherapy for bone, brain, and orbital metastases.

Keywords: Radiation recall dermatitis, breast cancer, orbital metastases

1. HISTORY

A 55-year-old woman was diagnosed with breast adenocarcinoma in August 2006. In late September, she complained of back pain and slight numbness. A bone scan revealed a mild increase in activity in the thoracic spine and the proximal fourth and anterior sixth ribs. Magnetic resonance imaging (mri) of the spine confirmed metastatic involvement in the tenth thoracic vertebra. The patient received radiotherapy with 20 Gy in 5 fractions in October 2006. She tolerated the treatment very well with complete pain relief.

The woman returned to her medical oncologist for systemic therapy. A combination of paclitaxel (175 mg/m2) and gemcitabine (1000 mg/m2) was commenced in November 2006. After receiving a single dose, the patient complained of double vision. A computed tomography examination confirmed left orbital metastases (Figure 1) and multiple intraparenchymal brain metastases in the left frontal lobe and left cerebellum. The woman was treated with whole-brain radiotherapy (wbrt), including the left orbit, which received a dose of 20 Gy in 5 fractions. The initial chemotherapy treatment took place 13 days before the commencement of the wbrt. No adverse reactions were observed immediately after the radiation treatment.

FIGURE 1.

FIGURE 1

Retrobulbar metastasis, axial, and coronal computed tomography images with contrast. (A) Axial view of the inferior orbits demonstrates enhancing abnormal soft tissue posterior and lateral to the left globe (arrow). (B) Axial view of the upper orbits demonstrates enhancing abnormal soft tissue in the medial left orbit inseparable from the medial rectus muscle (arrow). (C) Coronal view demonstrates abnormal soft tissue in the medial left orbit inseparable from the medial rectus (arrow) and in the lateral inferior left orbit inseparable from the inferior rectus and in contact with the optic nerve (arrowhead).

Ten days after completion of the wbrt, the patient received her second dose of paclitaxel and gemcitabine. Within 2 days, the patient detected discoloured and inflamed skin limited to the region that had previously been irradiated. She also experienced swelling in the left ear, muffled hearing, and discomfort in the eyes as a result of the reaction. Surprisingly, increased pigmentation also occurred in the area of the thoracic bone metastases treated with palliative radiotherapy approximately 7 weeks earlier. Silver sulphadiazine cream and hydrocortisone eardrops were prescribed to treat external symptoms. All chemotherapy was put on hold.

Approximately 4 weeks after development of the skin reaction, the patient developed new cervical nodes compatible with clinical progression of her breast cancer. Once the external skin reaction had improved significantly, with only mild discolouration remaining, chemotherapy was resumed. At this time, nearly 6 weeks had passed since the appearance of the radiation recall dermatitis (rrd). A chemotherapy regimen of cyclophosphamide (600 mg/m2), epirubicin (100 mg/m2), and 5-fluorouracil (600 mg/m2) replaced the paclitaxel and gemcitabine. Dexamethasone (Decadron: Merck, Whitehouse Station, NJ, U.S.A) was administered at 20 mg before the first chemotherapy treatment and at 10 mg before each subsequent treatment. No adverse reactions have occurred since. At follow-up, the patient’s double vision had improved, and a computed tomography scan revealed a stable appearance in the orbital metastases. New mri examination of the brain, orbits, and spine revealed no demyelination corresponding to the areas affected by the rrd reaction.

2. DISCUSSION

“Radiation recall”—also called rrd—is defined as the “recalling” by skin of previous radiation exposure in response to the administration of certain response-inducing drugs 1. In the medical world, the rrd phenomenon has been termed anything from “moderately rare” to “moderately common.” No exact cause or incidence has been documented2.

D’Angio and colleagues originally documented rrd in 1959 3; the trigger for the abnormal reaction was dactinomycin 1. Cytotoxics are common instigators 1. Some medications have been documented to be more commonly involved with rrd: docetaxel, doxorubicin, gemcitabine, and paclitaxel (Tables I and II). Although the association is only a loose one, Camidge and Price proposed that more-severe skin reactions are more common when the period between radiation and the recall-triggering drug is smaller 1. According to Putnik et al. 60, the median time between the conclusion of radiation treatment and the materialization of rrd is 39 days. In the present case, materialization of the rrd occurred within 2 days.

TABLE I.

I Radiation recall dermatitis (rrd): case summaries

Reference Condition treated Radiation dose Drug leading to rrda Time to rrd Treatment a
Tan et al., 1959 4 Ewing sarcoma of the left hip 10 Gy to the left knee and 17.5 Gy to the spine Dactinomycin (75 μg/kg) 7 days after completion of rt Unspecified Unspecified
D’Angio, 1962 3 Wilms tumour rt to the left lung and right paracardiac Dactinomycin During administra- tion of response- inducing drug Unspecified
Von Essen et al., 1963 5 Breast carcinoma 30 Gy 5-Fluorouracil (15 mg/kg daily for 4 days) 7 weeks after rt 2 Weeks Unspecified
Sears, 1964 6 Wilms tumour Postsurgical tumour-bed irradiation Hydroxyurea (60 mg/kg daily) 1 month after rt 5 Days Unspecified
Wilms tumour Radiation for pulmonary metastasis Hydroxyurea (60 mg/kg daily) 1 month after rt 9 Days Unspecified
Rhabdomyosarcoma of the cervical area 30 Gy Hydroxyurea (60 mg/kg daily) 47 days after rt 8 Days Unspecified
Rhabdomyosarcoma of the cervical area 16 Gy to site of pulmonary metastasis Hydroxyurea (60 mg/kg daily) 7 days after rt 16 Days Unspecified
Lampkin, 1969 7 Rhabdomyosarcoma of the right middle ear 56.44 Gy to the right face 28.32 Gy to the left side Vinblastine (0.2 mg/kg) 2 months after rt 1 Day Unspecified; same reaction occurred 2 weeks later
Jaffe et al., 1973 8 Osteogenic sarcoma 26.25 Gy Methotrexate (400 mg/kg) 24 hours after rt Unspecified Unspecified; rechallenged 2–3 weeks later with no recurrence
Donaldson et al., 1974 9 Fibrosarcoma of the right mandible 59.5 Gy Doxorubicin (Adriamycin: 60 mg/m2) 5 weeks after rt 7 Days Unspecified; rechallenged at weeks 7 and 15 at the same and reduced doses with identical reaction
Osteosarcoma of the fibula 59.5 Gy Doxorubicin (Adriamycin: 60 mg/m2) 1 week after rt 7 Days Unspecified; rechallenged after 12 weeks with identical reaction
Etcubanas and Wilbur, 1974 10 Mandibular fibrosarcoma Unspecified Doxorubicin (Adriamycin: 60 mg/m2) 4 weeks after rt Unspecified Unspecified; after second cycle, a milder skin reaction occurred
Unspecified Unspecified Doxorubicin (Adriamycin: 60 mg/m2) 1 week after rt Unspecified Unspecified; rechallenged twice, with identical reaction each time
Cassady et al., 1975 11 Lymphoma to the right axilla and supraclavicular fossa 12 Gy to mantle field Doxorubicin (Adriamycin: 75 mg/m2) 26 days after rt Hours Unspecified
Osteosarcoma to the left proximal humerus 24 Gy Doxorubicin (Adriamycin: 30 mg/m2 daily for 3 days) 18 days after rt 7 Days Unspecified
Rosen et al., 1975 12 Osteogenic sarcoma 16 Gy Methotrexate (200 mg/kg) 8 weeks after rt 5 Days Unspecified; rechallenged twice with similar reactions
Mayer et al., 1976 13 Metastatic breast cancer 45 Gy to the spine Doxorubicin (Adriamycin: 80 mg/injection, 1 injection per month for 9 months) given 7 years after rt 7 Months (at the time of the 7th injection) Unspecified
Fontana, 1979 14 Small-cell lung cancer 38 Gy Etoposide (100 mg/m2 on days 1–3) 7 days after rt 18 Hours Unspecified; rechallenged 3 weeks later, resulting in the same reaction
Solberg et al., 1980 15 Acute myelomonocytic leukemia and leukemia cutis 21 Gy whole-body irradiation Doxorubicin (Adriamycin: 35 mg/m2 daily for 3 days) given 2 days after rt 4 Days Death related to toxicity
Weiss et al., 1986 16 Advanced cancers Unspecified Intravenous trimetrexate (80 mg/m2 over 24 hours) every 28 days Unspecified Unspecified
Unspecified Intravenous trimetrexate (200 mg/m2 over 24 hours) every 28 days Unspecified Unspecified
Unspecified Intravenous trimetrexate (200 mg/m2 over 24 hours) every 28 days Unspecified Unspecified
Unspecified Intravenous trimetrexate (200 mg/m2 over 24 hours) every 28 days Unspecified Unspecified
Jolivet et al., 1987 17 Lung cancer 40 Gy Trimetrexate (2 mg/m2 bolus) for 9 consecutive days every 28 days for 2 cycles; begun 10 months after completion of rt Unspecified Unspecified
Kellie et al., 1987 18 Embryonal rhabdomyosarcoma of the legs 54 Gy Melphalan (200 mg/m2) 6 weeks after completion of rt 24 Hours Unspecified
Nemechek and Corder, 199219 Man (age 34) with hiv and a large Kaposi sarcoma lesion on the left foot 27 Gy in 15 fractions Intravenous vinblastine (10 mg/m2), begun 10 months after rt 48 Hours Healed by the 5th day after chemotherapy
Parry, 1992 20 Woman (age 70) with breast cancer Wide local excision and adjuvant rt 2 years earlier Tamoxifen (20 mg daily) started 2 years after rt 5 Days Discontinued tamoxifen; resolved in 2 weeks; rechallenged at 10 mg daily, with mild recurrence
Raghavan et al., 1993 21 Recurrent breast carcinoma 61.2 Gy to the chest wall; 65.3 Gy to the supraclavicular region Paclitaxel (130 mg/m2 over 24 h), begun 2 days after rt 5 Days Antibiotics, chest wall debridement
Stelzer et al., 199322 aids-related Kaposi sarcoma Each lesion randomized to 1 of 3 possible radiation fractionation schemes:1) 40 Gy in 20 fractions2) 40 Gy in 20 fractions3) 8 Gy in 1 fraction4) 20 Gy in 5 fractions Intravenous bleomycin (10 mg/m2) on a weekly basis 1) 3 Days after second injection2) 3 Days after second injection3) No rrd4) No rrd In 1) and 2), exacerbated by oral etoposide therapy started 4 days after appearance of the skin reaction
Shenkier and Gelman, 1994, as cited by Advanced gastric cancer 44 Gy Paclitaxel (90 mg/m2) 7 months after rt 3 Hours Mild recurrence when paclitaxel given in 7 further cycles
Camidge and Price, 2001 1 Advanced gastric cancer 44 Gy Paclitaxel (90 mg/m2) 8 months after rt 6 Hours No recurrence when paclitaxel given in 7 further cycles
Abadir and Liebmalen 1995 23 Woman (age 60) with adenocarcinoma of the gallbladder Tumour dose was 61.2 Gy in 34 fractions Simvastatin for hypercholesterolemia (20 mg daily), 11 months after rt 2–3 Days Prednisone and cephalotin
Extermann et al., 1995 24 Man (age 55) with ductal carcinoma of the right breast Tamoxifen (20 mg daily), plus 48.25 Gy with a 15-Gy boost to the tumour bed Isoniazid 400 mg, plus rifampicin 600 mg, plus pyrazinamide 2 mg to treat nasopharyngeal tuberculosis, 4 months after rt During 4th week of treatment All medications were continued, and the reaction gradually regressed in the weeks following
Perez et al., 1995 25 Woman (age 32) with metastatic breast cancer 30 Gy to the lumbar spine Edatrexate (100 mg/m2 biweekly), begun 6 weeks after rt After 3 doses (11 days) Topical therapy, nsaids; rechallenged with prednisone with mild recurrence
Phillips, 1995, as cited by Camidge and Price, 2001 1 Unknown 25 Gy Paclitaxel (90 mg/m2) given 27 days after rt 3 Days No recurrence when paclitaxel given in 3 further cycles
Schweitzer et al., 1995 26 Woman (age 61) with metastatic lung adenocarcinoma 43.2 Gy to the mediastinum; 46 Gy to the ribs Paclitaxel (175 mg/m2 over 3 hours), begun 12 days after rt completion Hours Dexamethasone (Decadron: 20 mg), diphenhydramine (50 mg); paclitaxel given with Decadron after 2 weeks with no recurrence
Bokenmeyer et al., 1996 27 Woman (age 55) with breast cancer 50 Gy to the breast; 54 Gy to the lymph nodes Paclitaxel (175 mg/m2 over 3 h), 13 months after rt 5 Days Discontinuation of paclitaxel
McCarty et al., 1996 28 Woman (age 51) with invasive lobular breast carcinoma 50.4 Gy in 28 fractions; mild skin erythema developed Paclitaxel (200 mg/m2), 7 days after rt 4 Days Healing within 10 days; treatment unspecified
Yeo et al., 1997 29 Woman (age 51) with breast cancer 30 Gy in 10 fractions to T10–L4 spine and pelvis Docetaxel (100 mg/m2) on 3-weekly basis and prior oral dexamethasone (Decadron) for 5 days 4 Days after second injection Dose reduction; no recurrence of rrd
Bostrom et al., 1999 30 Woman (age 48) with highly differentiated tuboloductal breast cancer 54 Gy Tamoxifen (20 mg/m2 daily) 28 months after rt 2 Months Local steroid cream, mometasone furoate, once daily for 10 days; skin appeared normal 7 weeks after discontinuing tamoxifen; after 8 weeks, restarted on toremifene without recurrence
Wilson et al., 1999 31 Woman (age 46) with breast cancer Unspecified Epirubicin 2 Weeks Surgical debridement and microvascular free-flap reconstruction
Camidge & Kunkler, 2000 32 Woman (age 50) with breast cancer 50 Gy in 20 fractions Cycle 2 of docetaxel (100 mg/m2) with dexamethasone (Decadron: 8 mg once daily for 3 days), 16 days after end of rt Within 7 days Docetaxel reduced to 75% and given 21 days later; steroids for 7 days without recurrence
Castellano et al., 2000 33 Man (age 61) with stage iv nsclc 24 Gy in 8 fractions Gemcitabine (1250 mg/m2 on days 1, 8, 15 per 28-day cycle) 4 weeks after completion of rt 8 Days (second dose) Oral dexamethasone (Decadron) and diphenhydramine; resolved 10 days later; treatment continued with other chemotherapies
Giesel et al., 2000 34 Woman with breast cancer Whole-brain irradiation: 2 Gy for 5 days weekly, up to 50 Gy Docetaxel restarted (30 mg/m2 weekly) Unspecified Unspecified
Woman with breast cancer Whole-brain irradiation: 2 Gy for 5 days weekly, for up to 50 Gy Docetaxel re-started (100 mg/m2 weekly) Unspecified Unspecified
Kharfan et al., 2000 35 Woman (age 25) with stage iv nodular sclerosis Hodgkin disease 30 Gy to lumbar spine and right proximal femur Methotrexate (10 mg/m2 on day +1 after bone marrow transplant; 15 mg/m2 on days +3, +6, and +11) 7 Days after transplant Hydrating emulsions (treated symptomatically)
Chan et al., 2001 36 Man (age 50) with a sigmoid carcinoma 41.4 Gy in 23 days Oxaliplatin-based chemotherapy (oxaliplatin, plus 5-fluorouracil, plus folinic acid), resumed 8 days after completion on rt 3 Days Aqueous cream and sodium fusidate ointment (Fucidin); chemotherapy discontinued and reaction settled after 2 weeks; 5-fluorouracil plus folinic acid alone resumed without recurrence
Kennedy and McAleer, 2001 37 Malignant melanoma to the right temple 30 Gy Dacarbazine (800 mg/m2 once every 3 weeks), begun 2 months after rt 10 Days Unspecified
Bar-Sela et al., 2001 38 Man (age 65) with lung adenocarcinoma RT to mediastinum and upper lobe Gemcitabine Unspecified Unspecified
Jeter et al., 2002 39 Woman (age 41) with breast cancer 30 Gy in 10 fractions to lumbar spine Gemcitabine (1000 mg/m2 every 2 weeks), plus trastuzumab (Herceptin) weekly for 4 weeks, 5.5 months after rt 2 Weeks Discontinuation of gemcitabine slowly resolved the skin reaction
Man (age 79) with nsclc 30 Gy in 10 fractions Gemcitabine (1000 mg/m2)
11 days after rt
10 Days Supportive care, alginate gel pads, bowel rest
Woman (age 63) with metastatic adenocarcinoma of unknown primary 30 Gy in 10 fractions, plus 25 Gy in 2 fractions (boost) Gemcitabine (1000 mg/m2), 3.4 months after rt 3 Days Intravenous steroids for 2 days with minimal response
Morkas et al., 2002 40 Woman (age 39) with infiltrating ductal carcinoma 50.4 Gy in 28 fractions, plus 10 Gy to tumour bed and 2 cm surrounding Docetaxel (100 mg/m2), plus prophylactic dexamethasone (Decadron) 10 Days Methylprednisone (80 mg twice daily); docetaxel at 75% induced a less severe reaction
Ortmann and Hohenberg, 2002 41 Woman (age 56) with breast cancer 30 Gy in 10 fractions to right hip Capecitabine (2000 mg twice daily for 14 days) 3 Days after completion of first course Unspecified
Piroth et al., 2002 42 Woman (age 40) with breast cancer 30.9 Gy upper-body irradiation, plus whole-brain and pelvis Docetaxel (30 mg/m2) started 1 week after rt 14 Days Discontinuation and anti-inflammatory agents
Thomas and Stea, 2002 43 Woman (age 29) with malignant melanoma of the scalp Excision, plus biweekly treatments of 6 Gy, totalling 30 Gy Intravenous interferon alfa-2b (20×109 IU) administered 5 days after completion of rt 6 Days Occlusive dressings with wound gel; resolved in 7 days
Ee and Yosipovitch, 2003 44 Woman (age 55) with metastatic breast cancer Photo-recall Chemotherapy with taxanes Unspecified Unspecified
Jimeno et al., 2003 45 Woman (age 53) with stage IV infiltrating ductal carcinoma 30 Gy to left femur Pegylated liposomal doxorubicin (40 mg/m2 on day 1 every 28 days), 4 weeks after completion of rt 12 Days Topical steroids (betamethasone dipropionate); completely resolved 14 days later
Keung et al., 2003 46 Woman (age 49) with breast cancer 50 Gy in 25 fractions following modified mastectomy Arsenic trioxide (0.15 mg/kg daily), for 5 days each week for 5 weeks Day 2 of week 3 Arsenic trioxide discontinued, topical triamcinolone/silver sulfadiazine cream started
Schwartz et al., 2003 47 Woman (age 37) with recurrent ovarian adenocarcinoma Palliative whole-pelvis rt: 45 Gy in 25 fractions 3 Months later, started on gemcitabine (800 mg/m2), every other week; reduced to 600 mg/m2 because of severe neutropenia Unspecified Ciprofloxacin (250 mg twice daily) with slight improvement; 2nd cycle after 2 weeks produced the same reaction within 24 hours
Muggia, 200448 Woman with breast cancer rt to supraclavicular, internal mammary, and axillary areas Doxorubicin with weekly trastuzumab 2–4 Weeks None; continued liposomal doxorubicin
Singer et al., 2004 49 Woman (age 88) with infiltrating ductal carcinoma 50.4 Gy, plus 10 Gy to tumour bed Tamoxifen (20 mg daily) 3 Months None; continued on tamoxifen; completely resolved 3 months later
Borgia et al., 2005 50 Woman (age 63) with infiltrating ductal carcinoma 50 Gy over 5 weeks Docetaxel (100 mg/m2), every 3 weeks started 1 week after rt 4 Days after second course Oral methylprednisone resulted in 10-day complete remission
Kandemir et al., 2005 51 Woman (age 55) with breast cancer 50 Gy over 5 weeks Docetaxel (100 mg/m2), plus oral dexamethasone (Decadron) for 3 days 11 Days None; complete resolution after 6 days; continued docetaxel with no recurrence
Marisavljevic et al., 2005 52 Woman (age 32) with stage iib Hodgkin lymphoma Total dose of 60 Gy Gemcitabine (1250 mg/m2 on days 1, 8, 15), plus oral dexamethasone (Decadron: 8 mg on days 1, 2, 8, 9, 15, 16) more than 2 years after rt 2 Days Skin reaction faded over 10 days without specific treatment; mild recurrence after each gemcitabine administration
Ash and Videtic, 2006 53 Woman (age 56) with infiltrating ductal carcinoma 50 Gy in 25 fractions, plus additional 10 Gy in 5 fractions to lumpectomy site Phentermine 1 year after rt Unspecified Prednisone 30 mg daily for 2 weeks; minimal discolouration after 4 weeks
Ayoola and Lee, 2006 54 Woman (age 54) with lung squamous cell carcinoma 64.8 Gy to thorax and mediastinum Cefotetan upon admission to hospital for cholecystitis 3 Days Cefotetan withdrawn; free of pain in 4 days
Barlesi et al., 2006 55 Woman (age 75) with primary lung adenocarcinoma; treated for breast cancer 27 years earlier Lumpectomy and adjuvant radiation to the breast 27 years earlier Pemetrexed (500 mg/m2); oral prednisone (40 mg) twice daily the day before, the day of, and the day after chemotherapy 3 Days Steroids (prednisone 1 mg/kg daily); improvement in 48 hours; resolution at 2 weeks
Fakih, 2006 56 White man (age 52) with pancreatic adenocarcinoma 1.8 Gy daily for 50.4 Gy total Gemcitabine (1000 mg/m2), for 3 weeks every 4-week-cycle Cycle 5 Withdrawal of gemcitabine resulted in spontaneous resolution
Kaya et al., 2006 57 Woman (age 41) with non-Hodgkin lymphoma UV radiation Methotrexate (high dose), plus cytarabine (high dose) Unspecified Cold compress; lesions resolved within a week (with hyperpigmentation)
Kundranda and Daw, 2006 58 Woman (age 48) with well-differentiated infiltrating ductal carcinoma 50 Gy with a boost of 14 Gy to the tumour bed Tamoxifen (20 mg daily) Within 1 week Oral cephalexin did not provide relief; tamoxifen discontinued, diphenhydramine given; after 12 weeks, restarted on tamoxifen with mild itchiness, but no recurrence
Mizumoto et al., 2006 59 Woman (age 76) with diffuse large B cell lymphoma of the left neck 36 Gy in 18 fractions to the left neck Docetaxel (60 mg/m2) every 3 weeks 1 year after rt 6 Days Gargle with a local anesthetic and topical corticosteroids; 80% of docetaxel dose was given 2 weeks later; milder recall phenomenon recurred after 1 week
Woman (age 60) with breast cancer 50 Gy in 20 fractions Docetaxel (30 mg/m2 weekly) restarted 14 days after rt Day 6 after second course of chemotherapy Topical corticosteroids; continued docetaxel therapy for 9 cycles
Putnik et al., 2006 60 Man (age 65) with squamous cell carcinoma of the epiglottis 64.8 Gy Hypericin 4 Weeks after rt, then again 1 year after rt Symptoms controlled by steroid cream, but disappeared only when hypericin was discontinued
Hird et al., 2007 (present article) Woman (age 55) with metastatic breast adenocarcinoma 1) 20 Gy in 5 fractions to the thoracic spine (October 2006) 2) Whole-brain radiation: 20 Gy in 5 fractions (November 2006) Paclitaxel (175 mg/m2) and gemcitabine (1000 mg/m2) administered 1.5 weeks after completion of whole-brain radiation 2 Days Silver sulphadiazine cream and hydrocortisone eardrops; discolouration still apparent after 8 weeks; started on cef with concurrent dexamethasone (Decadron) without recurrence
a

Holders of named pharmaceutical trademarks: Adriamycin: Pharmacia, Kalamazoo, MI, U.S.A.; Decadron: Merck and Co., Whitehouse Station, NJ, U.S.A.; Fucidin: Leo Pharma, Ballerup, Denmark; Herceptin: Genentech, San Francisco, CA, U.S.A.

rt = radiotherapy; nsaids = nonsteroidal anti-inflammatory drugs; nsclc = non-small-cell lung cancer; uv = ultraviolet; cef = cyclophospha-mide, epirubicin, 5-fluorouracil.

TABLE II.

Radiation recall dermatitis–inducing drugs (n = 75)1,461

Drug Frequency
(n) (%)
Docetaxel 10 13
Doxorubicin 10 13
Gemcitabine 8 11
Paclitaxel 8 11
Trimetrexate 5 7
Methotrexate 4 5
Hydroxyurea 4 5
Tamoxifen 4 5
Dactinomycin 2 3
Vinblastine 2 3
Others 18 24

Although the precise mechanism of action for rrd is not known, several mechanisms that may, or may not, lead to the development of radiation recall have been proposed. These mechanisms include changes in vascularization, dna repair, radiation-impaired epithelial function of stem cells, and increased sensitivity to drugs 1. Corticosteroids have been suggested to have some protective effects 61. We found that steroids are commonly used in the treatment of external symptoms and with the intention of preventing recurrent reactions during subsequent chemotherapy administration 23,25,26,30,32,33,39,40,43,45,46,50,53,55,59,60.

Most recall reactions have occurred when radiotherapy and chemotherapy are separated by less than 2 months (Table I). The present case demonstrates a maximum time frame of 7 weeks separating radiation and resumption of chemotherapy treatment. Of the total reported cases of rrd outlined here, only 27% (20/75) demonstrated a duration greater than 7 weeks in terms of time passed between completion of radiotherapy and commencement of chemotherapy 1,57,12,13,17,19,20,23,24,27,30,37,39,52,53,59.

Although rrd is a rare phenomenon, it poses a significant barrier to treatment for patients. The condition creates a paradox: patients and clinicians alike wish to proceed with the most desirable treatment in the given circumstances, but are unable to do so because of the rare skin reaction. The present report serves as a reminder to palliative health care professionals of the possible danger of a recall reaction if an insufficient period has passed between radiotherapy and commencement of a potential recall-inducing drug.

Acknowledgments

3. ACKNOWLEDGMENT

This study was supported by the Michael and Karen Goldstein Cancer Research Fund.

4. REFERENCES

  • 1.Camidge R, Price A. Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol. 2001;59:237–45. doi: 10.1016/s0167-8140(01)00328-0. [DOI] [PubMed] [Google Scholar]
  • 2.Ortmann E, Hohenberg G. Treatment side effects. Case 1. Radiation recall phenomenon after administration of capecitabine. J Clin Oncol. 2002;20:3029–34. doi: 10.1200/JCO.2002.20.13.3029. [DOI] [PubMed] [Google Scholar]
  • 3.D’Angio GJ. Clinical and biologic studies of actinomycin D roentgen irradiation. Am J Roentgenol. 1962;87:106–9. [PubMed] [Google Scholar]
  • 4.Tan CT, Dargeon HW, Burchenal JH. The effect of actinomycin D on cancer in childhood. Pediatrics. 1959;24:544–61. [PubMed] [Google Scholar]
  • 5.Von Essen CF, Kligerman MM, Calabresi P. Radiation and 5-fluorouracil: a controlled clinical study. Radiology. 1963;81:1018–26. doi: 10.1148/81.6.1018. [DOI] [PubMed] [Google Scholar]
  • 6.Sears ME. Erythema in areas of previous irradiation in patients treated with hydroxyurea (nsc-32065) Cancer Chemother Rep. 1964;40:31–2. [PubMed] [Google Scholar]
  • 7.Lampkin BC. Skin reaction to vinblastine. Lancet. 1969;1:891. doi: 10.1016/s0140-6736(69)91941-2. [DOI] [PubMed] [Google Scholar]
  • 8.Jaffe N, Paed D, Farber S, et al. Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy. Cancer. 1973;31:1367–73. doi: 10.1002/1097-0142(197306)31:6<1367::aid-cncr2820310611>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  • 9.Donaldson SS, Glick JM, Wilbur JR. Letter: Adriamycin activating a recall phenomenon after radiation therapy. Ann Intern Med. 1974;81:407–8. doi: 10.7326/0003-4819-81-3-407. [DOI] [PubMed] [Google Scholar]
  • 10.Etcubanas E, Wilbur JR. Letter: uncommon side effects of Adriamycin (nsc-123127) Cancer Chemother Rep. 1974;58:757–8. [PubMed] [Google Scholar]
  • 11.Cassady JR, Richter MP, Piro AJ, Jaffe N. Radiation– Adriamycin interactions: preliminary clinical observations. Cancer. 1975;36:946–9. doi: 10.1002/1097-0142(197509)36:3<946::aid-cncr2820360316>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  • 12.Rosen G, Tefft M, Martinez A, Cham W, Murphy ML. Combination chemotherapy and radiation therapy in the treatment of metastatic osteogenic sarcoma. Cancer. 1975;35:622–30. doi: 10.1002/1097-0142(197503)35:3<622::aid-cncr2820350313>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  • 13.Mayer EG, Poulter CA, Aristizabal SA. Complications of irradiation related to apparent drug potentiation by Adriamycin. Int J Radiat Oncol Biol Phys. 1976;1:1179–88. doi: 10.1016/0360-3016(76)90091-2. [DOI] [PubMed] [Google Scholar]
  • 14.Fontana JA. Radiation recall associated with vp-16–213 therapy. Cancer Treat Rep. 1979;63:224–5. [PubMed] [Google Scholar]
  • 15.Solberg LA, Jr, Wick MR, Bruckman JE. Doxorubicin-enhanced skin reaction after whole-body electron-beam irradiation for leukemia cutis. Mayo Clin Proc. 1980;55:711–15. [PubMed] [Google Scholar]
  • 16.Weiss RB, James WD, Major WB, Porter MB, Allegra CJ, Curt GA. Skin reactions induced by trimetrexate, an analog of methotrexate. Invest New Drugs. 1986;4:159–63. doi: 10.1007/BF00194596. [DOI] [PubMed] [Google Scholar]
  • 17.Jolivet J, Landry L, Pinard MF, McCormack JJ, Tong WP, Eisenhauer E. A phase i study of trimetrexate, an analog of methotrexate, administered monthly in the form of nine consecutive daily bolus injections. Cancer Chemother Pharmacol. 1987;20:169–72. doi: 10.1007/BF00253973. [DOI] [PubMed] [Google Scholar]
  • 18.Kellie SJ, Plowman PN, Malpas JS. Radiation recall and radiosensitization with alkylating agents. Lancet. 1987;1:1149–50. doi: 10.1016/s0140-6736(87)91711-9. [DOI] [PubMed] [Google Scholar]
  • 19.Nemechek PM, Corder MC. Radiation recall associated with vinblastine in a patient treated for Kaposi sarcoma related to acquired immune deficiency syndrome. Cancer. 1992;70:1605–6. doi: 10.1002/1097-0142(19920915)70:6<1605::aid-cncr2820700627>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  • 20.Parry BR. Radiation recall induced by tamoxifen. Lancet. 1992;340:49. doi: 10.1016/0140-6736(92)92460-w. [DOI] [PubMed] [Google Scholar]
  • 21.Raghavan VT, Bloomer WD, Merkel DE. Taxol and radiation recall dermatitis. Lancet. 1993;341:1354. doi: 10.1016/0140-6736(93)90871-d. [DOI] [PubMed] [Google Scholar]
  • 22.Stelzer KJ, Griffin TW, Koh WJ. Radiation recall skin toxicity with bleomycin in a patient with Kaposi sarcoma related to acquired immune deficiency syndrome [abstract] Cancer. 1993;71:1322–5. doi: 10.1002/1097-0142(19930215)71:4<1322::aid-cncr2820710425>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  • 23.Abadir R, Leibmann J. Radiation reaction recall following simvastatin therapy: a new observation. Clin Oncol (R Coll Radiol) 1995;7:325–6. doi: 10.1016/s0936-6555(05)80545-x. [DOI] [PubMed] [Google Scholar]
  • 24.Extermann M, Vogt N, Forni M, Dayer P. Radiation recall in a patient with breast cancer treated for tuberculosis. Eur J Pharmacol. 1995;48:77–8. doi: 10.1007/BF00202177. [DOI] [PubMed] [Google Scholar]
  • 25.Perez EA, Campbell DL, Ryu JK. Radiation recall dermatitis induced by edatrexate in a patient with breast cancer. Cancer Invest. 1995;13:604–7. doi: 10.3109/07357909509024929. [DOI] [PubMed] [Google Scholar]
  • 26.Schweitzer VG, Julliard GJ, Bajada CL, Parker RG. Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel. Cancer. 1995;76:1069–72. doi: 10.1002/1097-0142(19950915)76:6<1069::aid-cncr2820760623>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  • 27.Bokemeyer C, Lampe C, Heneka M, Schabet M, Bamberg M, Kanz L. Paclitaxel-induced radiation recall dermatitis. Ann Oncol. 1996;7:755–77. doi: 10.1093/oxfordjournals.annonc.a010730. [DOI] [PubMed] [Google Scholar]
  • 28.McCarty MJ, Peake MF, Lillis P, Vukelja SJ. Paclitaxel-induced radiation recall dermatitis. Med Pediatr Oncol. 1996;27:185–6. doi: 10.1002/(SICI)1096-911X(199609)27:3<185::AID-MPO9>3.0.CO;2-A. [DOI] [PubMed] [Google Scholar]
  • 29.Yeo W, Leung SF, Johnson PJ. Radiation-recall dermatitis with docetaxel: establishment of a requisite radiation threshold. Eur J Cancer. 1997;33:698–9. doi: 10.1016/s0959-8049(96)00461-3. [DOI] [PubMed] [Google Scholar]
  • 30.Bostrom A, Sjolin–Forsberg G, Wilking N, Bergh J. Radiation recall: another call with tamoxifen. Acta Oncologica. 1999;38:955–9. doi: 10.1080/028418699432653. [DOI] [PubMed] [Google Scholar]
  • 31.Wilson J, Carder P, Gooi J, Nishikawa H. Recall phenomenon following epirubicin [abstract] Clin Oncol (R Coll Radiol) 1999;11:424–5. doi: 10.1053/clon.1999.9099. [DOI] [PubMed] [Google Scholar]
  • 32.Camidge DR, Kunkler IH. Docetaxel-induced radiation recall dermatitis and successful rechallenge without recurrence. Clin Oncol (R Coll Radiol) 2000;12:272–3. [PubMed] [Google Scholar]
  • 33.Castellano D, Hitt R, Cortes–Funes H, Romero A, Rodriguez– Peralto JL. Side effects of chemotherapy: case 2. Radiation recall induced by gemcitabine. J Clin Oncol. 2000;18:693–8. doi: 10.1200/JCO.2000.18.3.695. [DOI] [PubMed] [Google Scholar]
  • 34.Giesel BU, Kutz GG, Thiel HJ. Recall dermatitis caused by re-exposure to docetaxel following irradiation of the brain. Case report and review of the literature [abstract, German] Strahlenther Onkol. 2001;117:487–93. doi: 10.1007/pl00002431. [DOI] [PubMed] [Google Scholar]
  • 35.Kharfan Dabaja MA, Morgensztern D, Markoe AM, Bartlett– Pandite L. Radiation recall induced by methotrexate with in a patient with Hodgkin’s disease. Am J Clin Oncol. 2000;23:531–3. doi: 10.1097/00000421-200010000-00020. [DOI] [PubMed] [Google Scholar]
  • 36.Chan RT, Au GK, Ho JW, Chu KW. Radiation recall with oxaliplatin: report of a case and review of the literature. Clin Oncol (R Coll Radiol) 2001;13:55–7. doi: 10.1053/clon.2001.9216. [DOI] [PubMed] [Google Scholar]
  • 37.Kennedy RD, McAleer JJ. Radiation recall dermatitis in a patient treated with dacarbazine. Clin Oncol (R Coll Radiol) 2001;13:470–2. doi: 10.1053/clon.2001.9316. [DOI] [PubMed] [Google Scholar]
  • 38.Bar-Sela G, Beny A, Bergman R, Kuten A. Gemcitabine-induced radiation recall dermatitis: case report [abstract] Tumori. 2001;87:428–30. doi: 10.1177/030089160108700614. [DOI] [PubMed] [Google Scholar]
  • 39.Jeter MD, Janne PA, Brooks S, et al. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys. 2002;53:394–400. doi: 10.1016/s0360-3016(02)02773-6. [DOI] [PubMed] [Google Scholar]
  • 40.Morkas M, Fleming D, Hahl M. Challenges in oncology. Case 2. Radiation recall associated with docetaxel. J Clin Oncol. 2002;20:867–9. doi: 10.1200/JCO.2002.20.3.867. [DOI] [PubMed] [Google Scholar]
  • 41.Ortmann E, Hohenberg G. Treatment side effects: case 1. Radiation recall phenomenon after administration of capecitabine. J Clin Oncol. 2002;20:3029–30. doi: 10.1200/JCO.2002.20.13.3029. [DOI] [PubMed] [Google Scholar]
  • 42.Piroth MD, Krempien R, Wannenmacher M, Zierhut D. Radiation recall dermatitis from docetaxel [abstract] Onkologie. 2002;25:438–40. doi: 10.1159/000067438. [DOI] [PubMed] [Google Scholar]
  • 43.Thomas R, Stea B. Radiation recall dermatitis from high-dose interferon alfa-2b. J Clin Oncol. 2002;20:355–7. doi: 10.1200/JCO.2002.20.1.355. [DOI] [PubMed] [Google Scholar]
  • 44.Ee HL, Yosipovitch G. Photo recall phenomenon: an adverse reaction to taxanes. Dermatology. 2003;207:196–8. doi: 10.1159/000071795. [DOI] [PubMed] [Google Scholar]
  • 45.Jimeno A, Cirelos EM, Castellano D, Caballero B, Rodriguez– Peralto JL, Cortes–Funes H. Radiation recall dermatitis induced by pegylated liposomal doxorubicin. Anticancer Drugs. 2003;14:575–6. doi: 10.1097/00001813-200308000-00011. [DOI] [PubMed] [Google Scholar]
  • 46.Keung YK, Lyerly ES, Powell BL. Radiation recall phenomenon associated with arsenic trioxide. Leukemia. 2003;17:1417–36. doi: 10.1038/sj.leu.2402992. [DOI] [PubMed] [Google Scholar]
  • 47.Schwartz BM, Khuntia D, Kennedy AW, Markman M. Gemcitabine-induced radiation recall dermatitis following whole pelvic radiation therapy. Gynecol Oncol. 2003;91:421–2. doi: 10.1016/s0090-8258(03)00404-9. [DOI] [PubMed] [Google Scholar]
  • 48.Muggia FM. Re: “Radiation recall dermatitis induced by pegylated liposomal doxorubicin. Anticancer Drugs. 2004;15:35. doi: 10.1097/00001813-200401000-00006. [DOI] [PubMed] [Google Scholar]
  • 49.Singer EA, Warren RD, Pennanen MF, Collins BT, Hayes DF. Tamoxifen-induced radiation recall dermatitis. Breast J. 2004;10:170–1. doi: 10.1111/j.1075-122x.2004.21222.x. [DOI] [PubMed] [Google Scholar]
  • 50.Borgia F, Guarneri C, Guarneri F, Vaccaro M. Radiation recall dermatitis after docetaxel administration: absolute indication to replace the drug? Br J Dermatol. 2005;153:674–5. doi: 10.1111/j.1365-2133.2005.06801.x. [DOI] [PubMed] [Google Scholar]
  • 51.Kandemir EG, Karabudak O, Maydagli A. Docetaxel-induced radiation recall dermatitis. Swiss Med Wkly. 2005;135:34–5. doi: 10.4414/smw.2005.10896. [DOI] [PubMed] [Google Scholar]
  • 52.Marisavljevic D, Ristic B, Hajder J. Gemcitabine-induced radiation recall dermatitis in a patient with resistant Hodgkin lymphoma. Am J Hematol. 2005;80:87–93. doi: 10.1002/ajh.20379. [DOI] [PubMed] [Google Scholar]
  • 53.Ash RB, Videtic GM. Radiation recall dermatitis after the use of anorexiant phentermine in a patient with breast cancer. Breast J. 2006;12:186–7. doi: 10.1111/j.1075-122X.2006.00235.x. [DOI] [PubMed] [Google Scholar]
  • 54.Ayoola A, Lee YJ. Radiation recall dermatitis with cefotetan: a case study. Oncologist. 2006;11:1118–20. doi: 10.1634/theoncologist.11-10-1118. [DOI] [PubMed] [Google Scholar]
  • 55.Barlesi F, Tummino C, Taset AM, Astoul P. Unsuccessful rechallenge with pemetrexed after previous radiation recall dermatitis. Lung Cancer. 2006;54:423–5. doi: 10.1016/j.lungcan.2006.06.021. [DOI] [PubMed] [Google Scholar]
  • 56.Fakih MG. Gemcitabine-induced rectus abdominus radiation recall. JOP. 2006;7:306–10. [PubMed] [Google Scholar]
  • 57.Kaya TI, Tiftik N, Tursen U, Ikizoglu G, Yalcin A. Ultraviolet recall phenomenon associated with methotrexate and cytarabine. J Eur Acad Dermatol Venereol. 2006;20:353–4. doi: 10.1111/j.1468-3083.2006.01432.x. [DOI] [PubMed] [Google Scholar]
  • 58.Kundranda MN, Daw HA. Tamoxifen-induced radiation recall dermatitis. Am J Clin Oncol. 2006;29:637–8. doi: 10.1097/01.coc.0000189693.23157.8d. [DOI] [PubMed] [Google Scholar]
  • 59.Mizumoto M, Harada H, Asakura H, et al. Frequency and characteristics of docetaxel-induced radiation recall phenomenon. Int J Radiat Oncol Biol Phys. 2006;66:1187–91. doi: 10.1016/j.ijrobp.2006.05.073. [DOI] [PubMed] [Google Scholar]
  • 60.Putnik K, Stadler P, Schafer C, Koelbl O. Enhanced radiation sensitivity and radiation recall dermatitis (rrd) after hypericin therapy—case report and review of the literature. Radiat Oncol. 2006;1:32. doi: 10.1186/1748-717X-1-32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Azria D, Magne N, Zouhair A, et al. Radiation recall: a well recognized but neglected phenomenon. Cancer Treat Rev. 2005;31:555–70. doi: 10.1016/j.ctrv.2005.07.008. [DOI] [PubMed] [Google Scholar]

Articles from Current Oncology are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES